bluebird bio Inc (BLUE) Given Average Rating of “Hold” by Brokerages

bluebird bio Inc (NASDAQ:BLUE) has been given a consensus rating of “Hold” by the twenty-five analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $162.56.

BLUE has been the subject of several research reports. Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 price target on shares of bluebird bio in a research note on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and set a $170.00 price target (up previously from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. BMO Capital Markets lifted their price target on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. BTIG Research raised bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price target for the company in a research note on Thursday, November 2nd. Finally, SunTrust Banks lifted their price target on bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd.

bluebird bio (NASDAQ BLUE) traded down $6.15 during trading on Tuesday, reaching $175.95. The company’s stock had a trading volume of 733,163 shares, compared to its average volume of 1,140,000. bluebird bio has a 12 month low of $64.15 and a 12 month high of $222.03. The firm has a market capitalization of $8,060.00, a P/E ratio of -25.10 and a beta of 2.08.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same period last year, the firm earned ($2.07) EPS. equities analysts anticipate that bluebird bio will post -6.72 EPS for the current fiscal year.

In related news, Director Mark Vachon sold 7,000 shares of bluebird bio stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $216.64, for a total transaction of $1,516,480.00. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at approximately $1,733,120. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Nick Leschly sold 117,500 shares of bluebird bio stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $184.08, for a total value of $21,629,400.00. Following the sale, the insider now owns 293,232 shares of the company’s stock, valued at approximately $53,978,146.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 208,095 shares of company stock valued at $36,841,014. 3.90% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC grew its holdings in bluebird bio by 9.6% in the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares during the period. Capital Research Global Investors grew its holdings in bluebird bio by 9.9% in the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares during the period. Vanguard Group Inc. grew its holdings in bluebird bio by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares during the period. BlackRock Inc. grew its holdings in bluebird bio by 4.3% in the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares during the period. Finally, Northern Trust Corp grew its holdings in bluebird bio by 11.7% in the 2nd quarter. Northern Trust Corp now owns 518,673 shares of the biotechnology company’s stock valued at $54,487,000 after buying an additional 54,142 shares during the period.

WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://weekherald.com/2018/01/22/bluebird-bio-inc-blue-given-average-rating-of-hold-by-brokerages.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply